

**AMENDMENTS TO THE CLAIMS**

**This listing of claims will replace all prior versions and listings of claims in the application:**

**LISTING OF CLAIMS:**

1-7. (canceled).

8. (currently amended): An inhibitor of Rb protein dephosphorylation containing 20-O-β-D-glucopyranosyl-20(S)- protopanaxatriol (“ginsenoside F1”) and (-)-epigallocatechin-3-gallate (“EGCG”) as active ingredients, wherein the weight ratio of ginsenoside F1 : EGCG is in the range of 1:0.1 – 1: 10 and wherein said ginsenoside F1 and EGCG are incorporated in a combined amount of 0.0001% to 10% by weight based on the total weight of the composition.

9-10. (canceled).

11. (currently amended): The composition according to ~~claim 1~~claim 8, wherein the weight ratio of ginsenoside F1 : EGCG is 1:5.